Ragnar Metals Limited

RAG

Ragnar Metals Ltd. engages in the business of exploring and evaluating nickel, gold, silver, and base metals projects in Scandinavia and Australia. The company is headquartered in Perth, Western Australia. The company went IPO on 2005-03-31. The firm is engaged in the exploration and evaluation of its projects in Scandinavia and commencement of the exploration and evaluation of its Australian projects. Its projects consist of Halleberget Lithium Project, Bergom Lithium Project, Orrvik Lithium Project, Leeds Project, and Kenya Project. The Halleberget Project is located 10 km along strike to the north of Sweden's lithium pegmatite resource at Jarkvissle. The Bergom project is located 100 km east-northeast of Halleberget and is in an area of known LCT pegmatites. Oslerum North HREE Project tenure comprises 20.8 square kilometer (km2), located 8.5 km north of the Olserum HREE deposit. Gruvhagen REE (NdPr) Project tenure comprises 16.5 km2 tenure, located 20 km north of Ragnar Metals Granmuren nickel (Ni)-copper (Cu) discovery. The Orrvik Lithium Project comprises of 36 km2 of highly prospective tenure.

Race Oncology Ltd

RAC

Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. The firm is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. The company is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.

Radiopharm Theranostics Limited

RAD

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The company has a pipeline of differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the universities and institutes around the world. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including lung, pancreas and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.